Highlights Valerio Therapeutics

Equities

ALVIO

FR0010095596

Real-time Euronext Paris Other stock markets 03:52:25 09/05/2024 pm IST			5-day change	1st Jan Change
0.11 ^EUR	0.00%		+2.61%	-33.33%

30/04	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	01/05	CI
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	25/23/25	CI
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	30/22/30	CI
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	14/22/14	CI
Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie	01/22/01	CI
Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA	01/22/01	CI
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2021	06/22/06	CI
Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022	31/22/31	CI
Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors	09/22/09	CI
Onxeo SA Announces New Preclinical Data Confirm the Ability of Asidna™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments	08/21/08	CI
Onxeo Sa Reports Earnings Results for the Half Year Ended June 30, 2021	29/21/29	CI
Onxeo S.A. Receives Notice of Allowance for New Patent Broadening the Protection of AsiDNA™ in Combination with a PARP Inhibitor in the United States	09/21/09	CI
Onxeo S A : Creates Scientific Advisory Committee For Cancer Therapy Development	31/21/31	MT
Global markets live: Chevron, Toyota, Sony...	22/21/22
Onxeo to Present New Preclinical Data at AACR 2021	08/21/08	CI
Rights Issue: 1 new share @ 0.71 EUR for 6 existing shares	17/21/17	FA
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDN	04/21/04	CI
Onxeo S.A. Announces Completion of Patient Enrollment in DRIIV-1b Study	09/20/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Valerio Therapeutics

Equities

ALVIO

FR0010095596

Highlights

Filters